PeptideCompareSemaglutide — research peptide vs Ozempic.
Semaglutide is the GLP-1 receptor agonist approved as Ozempic (diabetes) and Wegovy (obesity). As a research peptide in Europe it is available from a limited number of vendors — understanding the difference from the pharmaceutical product is essential.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying and improves glycaemic control. The pharmaceutical versions (Ozempic, Wegovy, Rybelsus) are EMA-approved and available on prescription in Europe. Research-grade semaglutide is the same molecule sold as a lyophilized powder for laboratory research — produced and tested to varying standards, without the GMP controls, sterility testing and known dosing of the approved drug.
What does the research show?
What to look for when buying in Europe
Few EU vendors carry semaglutide due to its pharmaceutical status — PeptideCompare tracks limited suppliers. Purity verification is critical at this price point. Require ≥98% HPLC and mass-spec from a named lab. Be wary of suspiciously cheap offers.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Compare Semaglutide across EU suppliers
2 EU vendors · COA-verified · from €64.95 · Updated monthly
Frequently asked questions
What is research-grade semaglutide? ▾
Research-grade semaglutide is the same GLP-1 receptor agonist molecule as the approved pharmaceuticals (Ozempic, Wegovy, Rybelsus), sold as a lyophilized powder for laboratory research. It is produced and tested to varying standards, without the GMP controls, sterility testing and defined dosing of the approved drug.
Is semaglutide approved in Europe? ▾
The pharmaceutical versions (Ozempic, Wegovy, Rybelsus) are EMA-approved and available on prescription in Europe. Research-grade semaglutide is a separate product category for laboratory use only and is not a medicine.
What does the clinical research show? ▾
The evidence base is strong. The STEP trial series showed roughly 15% mean body-weight reduction at 68 weeks, the SUSTAIN series supports glycaemic control, and the 2023 SELECT trial reported a significant reduction in major adverse cardiovascular events in overweight and obese patients.
How does research-grade differ from the pharmaceutical? ▾
It is the same molecule, but manufactured and tested to varying standards without the GMP controls, sterility testing and known dosing of the approved product. Anyone with a medical indication should obtain the approved pharmaceutical through a licensed physician and pharmacy.
Is semaglutide banned in sport? ▾
Yes. It is classed as WADA Prohibited S0, so its use is banned in competitive sport.
How do I verify quality when buying in Europe? ▾
Few EU vendors carry semaglutide because of its pharmaceutical status. Require a batch-specific COA showing at least 98% HPLC purity with mass-spec identity confirmation from a named laboratory, and be wary of suspiciously cheap offers.
References
- STEP 1, phase 3: in 1,961 adults with overweight or obesity, once-weekly semaglutide 2.4 mg alongside lifestyle intervention gave a mean weight change of −14.9% at 68 weeks against −2.4% on placebo. Wilding JPH, et al. N Engl J Med. 2021;384(11):989–1002. DOIPubMed 33567185
- STEP 3: semaglutide added to intensive behavioural therapy, the trial that isolates the drug effect on top of a structured lifestyle programme rather than against minimal support. Wadden TA, et al. JAMA. 2021;325(14):1403–1413. DOIPubMed 33625476
- STEP 4, randomised withdrawal: participants switched to placebo after 20 weeks regained weight while those continuing semaglutide kept losing. This is the trial behind the statement that the effect depends on continued use. Rubino D, et al. JAMA. 2021;325(14):1414–1425. DOIPubMed 33755728
- SELECT, cardiovascular outcome trial in 17,604 patients with established cardiovascular disease and overweight or obesity but without diabetes: a 20% relative reduction in major adverse cardiovascular events (hazard ratio 0.80, 95% CI 0.72–0.90). Lincoff AM, et al. N Engl J Med. 2023;389(24):2221–2232. DOIPubMed 37952131